Full Press Release Details
argenx to Present Data from Phase 2 Trial of Efgartigimod in Pemphigus at 2020 Society for Investigative Dermatology (SID) Virtual Annual Meeting.
ARGX
argenx to Present Data from Phase 2 Trial of Efgartigimod in Pemphigus at 2020 Society for Investigative Dermatology (SID) Virtual Annual Meeting
Key Takeaway: argenx to Present Data from Phase 2 Trial of Efgartigimod in Pemphigus at 2020 Society for Investigative Dermatology (SID) Virtual Annual Meeting
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+36%
120-day peak, hindsight
Typical move
4.7%
average across 12 past catalysts
Lead asset
Empasiprubart
Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis